

# Antonio Palumbo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3239926/publications.pdf>

Version: 2024-02-01

269  
papers

34,087  
citations

13099

68  
h-index

3650

180  
g-index

270  
all docs

270  
docs citations

270  
times ranked

16941  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	10.7	3,343
2	Multiple Myeloma. New England Journal of Medicine, 2011, 364, 1046-1060.	27.0	2,109
3	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
4	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. New England Journal of Medicine, 2008, 359, 906-917.	27.0	1,787
5	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology, 2015, 33, 2863-2869.	1.6	1,525
6	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 375, 754-766.	27.0	1,246
7	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2015, 372, 142-152.	27.0	1,144
8	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2015, 373, 621-631.	27.0	1,139
9	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 374, 1621-1634.	27.0	861
10	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 2011, 117, 4691-4695.	1.4	849
11	Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, 22, 414-423.	7.2	787
12	Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, The, 2006, 367, 825-831.	13.7	775
13	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncology, The, 2016, 17, 27-38.	10.7	723
14	Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1759-1769.	27.0	692
15	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, 2016, 127, 2955-2962.	1.4	686
16	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. New England Journal of Medicine, 2014, 371, 895-905.	27.0	683
17	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood, 2015, 125, 2068-2074.	1.4	586
18	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. Journal of Clinical Oncology, 2017, 35, 3279-3289.	1.6	535

#	ARTICLE	IF	CITATIONS
19	IMWG consensus on risk stratification in multiple myeloma. <i>Leukemia</i> , 2014, 28, 269-277.	7.2	500
20	Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 2259-2266.	1.6	403
21	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 5101-5109.	1.6	400
22	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. <i>Blood</i> , 2010, 116, 4745-4753.	1.4	361
23	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. <i>Lancet Haematology</i> , 2016, 3, e196-e204.	4.6	344
24	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. <i>Blood</i> , 2008, 112, 3107-3114.	1.4	339
25	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	1.6	330
26	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-664.	1.6	330
27	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011, 118, 4519-4529.	1.4	309
28	Thalidomide for treatment of multiple myeloma: 10 years later. <i>Blood</i> , 2008, 111, 3968-3977.	1.4	294
29	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	1.6	294
30	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	3.5	289
31	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 1617-1629.	10.7	289
32	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011, 117, 4696-4700.	1.4	285
33	Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. <i>Leukemia</i> , 2014, 28, 1299-1307.	7.2	257
34	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , 2014, 15, 333-342.	10.7	256
35	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. <i>Blood</i> , 2011, 117, 3025-3031.	1.4	247
36	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	10.7	219

#	ARTICLE	IF	CITATIONS
37	Management of treatment-emergent peripheral neuropathy in multiple myeloma. <i>Leukemia</i> , 2012, 26, 595-608.	7.2	217
38	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). <i>Leukemia</i> , 2014, 28, 525-542.	7.2	214
39	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. <i>Blood</i> , 2016, 127, 2833-2840.	1.4	207
40	Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. <i>Leukemia</i> , 2016, 30, 1005-1017.	7.2	204
41	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-640.	1.6	198
42	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013, 98, 980-987.	3.5	193
43	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264.	13.7	187
44	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , 2016, 127, 681-695.	1.4	179
45	IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , 2012, 119, 3003-3015.	1.4	178
46	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.	6.2	170
47	International Myeloma Working Group recommendations for global myeloma care. <i>Leukemia</i> , 2014, 28, 981-992.	7.2	162
48	Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1599-1605.	1.6	142
49	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3459-3466.	1.6	138
50	Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. <i>Blood</i> , 2014, 124, 63-69.	1.4	126
51	18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. <i>Leukemia</i> , 2016, 30, 417-422.	7.2	120
52	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <sc>Eloquent</sc> follow-up and <i>post-hoc</i> analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017, 178, 896-905.	2.5	120
53	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. <i>Blood</i> , 1993, 81, 2708-2713.	1.4	116
54	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 652-660.	2.8	115

#	ARTICLE	IF	CITATIONS
55	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	1.4	110
56	Second primary malignancies in multiple myeloma: an overview and IMWG consensus. <i>Annals of Oncology</i> , 2017, 28, 228-245.	1.2	102
57	Cancer-Selective Targeting of the NF- $\kappa$ B Survival Pathway with GADD45 $\beta$ /MKK7 Inhibitors. <i>Cancer Cell</i> , 2014, 26, 495-508.	16.8	99
58	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , 2016, 128, 1821-1828.	1.4	98
59	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). <i>Leukemia</i> , 2017, 31, 107-114.	7.2	98
60	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	3.7	90
61	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	1.4	90
62	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016, 127, 1102-1108.	1.4	78
63	Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. <i>Leukemia</i> , 2014, 28, 222-225.	7.2	77
64	Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. <i>Leukemia</i> , 2016, 30, 526-535.	7.2	76
65	Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. <i>Leukemia</i> , 2015, 29, 689-695.	7.2	75
66	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	6.2	75
67	Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 8-17.e16.	0.4	74
68	Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. <i>Haematologica</i> , 2013, 98, 87-94.	3.5	73
69	Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival. <i>Clinical Cancer Research</i> , 2011, 17, 1253-1263.	7.0	72
70	Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. <i>Leukemia</i> , 2017, 31, 2426-2434.	7.2	72
71	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	1.6	70
72	Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. <i>Journal of Proteomics</i> , 2016, 136, 89-98.	2.4	68

#	ARTICLE	IF	CITATIONS
73	Management of older adults with multiple myeloma. Blood Reviews, 2013, 27, 133-142.	5.7	67
74	Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.. Journal of Clinical Oncology, 2019, 37, 8002-8002.	1.6	67
75	Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood, 2015, 125, 449-456.	1.4	60
76	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. Journal of Clinical Oncology, 2020, 38, 4030-4041.	1.6	56
77	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. Blood, 2013, 122, 767-767.	1.4	56
78	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia, 2014, 28, 1922-1926.	7.2	55
79	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget, 2015, 6, 17543-17558.	1.8	55
80	Carfilzomib+“lenalidomide+“dexamethasone vs lenalidomide+“dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer Journal, 2017, 7, e554-e554.	6.2	54
81	Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Therapeutic Advances in Drug Safety, 2012, 3, 255-266.	2.4	51
82	Age and aging in blood disorders: multiple myeloma. Haematologica, 2014, 99, 1133-1137.	3.5	50
83	Carfilzomib+“dexamethasone vs bortezomib+“dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia, 2017, 31, 1368-1374.	7.2	50
84	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood, 1988, 72, 1064-1068.	1.4	48
85	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 2021, 11, 40.	6.2	46
86	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood, 1988, 72, 1064-1068.	1.4	44
87	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica, 2014, 99, 1114-1122.	3.5	42
88	How to Manage Neutropenia in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 5-11.	0.4	40
89	Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 519-530.	0.4	40
90	Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).. Journal of Clinical Oncology, 2016, 34, 8001-8001.	1.6	40

#	ARTICLE	IF	CITATIONS
91	Lenalidomide: A new therapy for multiple myeloma. <i>Cancer Treatment Reviews</i> , 2008, 34, 283-291.	7.7	39
92	Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. <i>Leukemia</i> , 2018, 32, 1803-1807.	7.2	39
93	A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. <i>Leukemia</i> , 2016, 30, 1320-1326.	7.2	38
94	Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 152-160.	0.4	34
95	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , 2020, 13, 421-433.	2.2	34
96	Have drug combinations supplanted stem cell transplantation in myeloma?. <i>Blood</i> , 2012, 120, 4692-4698.	1.4	33
97	The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). <i>Oncotarget</i> , 2016, 7, 9666-9679.	1.8	33
98	Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2016, 30, 1211-1214.	7.2	33
99	Tumor-Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2017, 15, 329-335.	1.8	33
100	Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. <i>Oncotarget</i> , 2017, 8, 5924-5935.	1.8	33
101	Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. <i>Cancer</i> , 2019, 125, 750-760.	4.1	31
102	Clinical characteristics of patients with relapsed multiple myeloma. <i>Cancer Treatment Reviews</i> , 2015, 41, 827-835.	7.7	30
103	Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 84-84.	1.4	30
104	Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. <i>Haematologica</i> , 2020, 105, 1937-1947.	3.5	29
105	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , 2016, 57, 2833-2838.	1.3	27
106	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 4.	17.0	27
107	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). <i>Blood</i> , 2015, 126, 4250-4250.	1.4	27
108	Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. <i>Leukemia</i> , 2018, 32, 979-985.	7.2	25



#	ARTICLE	IF	CITATIONS
109	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 27-35.	4.4	25
110	Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial. <i>Haematologica</i> , 2019, 104, 2265-2273.	3.5	23
111	A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 613-613.	1.4	23
112	Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. <i>Haematologica</i> , 2019, 104, 1640-1647.	3.5	22
113	Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 140-140.	1.4	22
114	Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 673-678.	2.4	21
115	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. <i>Annals of Hematology</i> , 2021, 100, 2325-2337.	1.8	21
116	A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2013, 122, 763-763.	1.4	20
117	Time to first disease progression, but not $\beta_2$ -microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. <i>Cancer</i> , 2007, 110, 824-829.	4.1	19
118	Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. <i>American Journal of Hematology</i> , 2017, 92, 244-250.	4.1	19
119	Optimizing Treatment for Elderly Patients With Newly Diagnosed Multiple Myeloma: A Personalized Approach. <i>Journal of Clinical Oncology</i> , 2016, 34, 3600-3604.	1.6	18
120	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. <i>Blood</i> , 2009, 114, 2878-2878.	1.4	18
121	Diagnosis and therapy of multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2013, 28, 263.	1.7	17
122	Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins. <i>Leukemia and Lymphoma</i> , 2016, 57, 537-556.	1.3	17
123	A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens. <i>Blood</i> , 2008, 112, 3017-3017.	1.4	17
124	A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen.. <i>Blood</i> , 2010, 116, 1092-1092.	1.4	17
125	Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age. <i>Blood</i> , 2013, 122, 539-539.	1.4	17
126	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020, 105, 1074-1080.	3.5	16



#	ARTICLE	IF	CITATIONS
127	Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.. Blood, 2009, 114, 128-128.	1.4	16
128	Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial. Blood, 2011, 118, 476-476.	1.4	16
129	Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial. Blood, 2011, 118, 811-811.	1.4	16
130	Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors. Annals of Oncology, 2015, 26, 2247-2256.	1.2	15
131	A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients. Blood, 2013, 122, 687-687.	1.4	15
132	Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.. Journal of Clinical Oncology, 2013, 31, 8509-8509.	1.6	15
133	Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.. Journal of Clinical Oncology, 2017, 35, 8011-8011.	1.6	15
134	Maintenance Therapy for Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 839-859.	2.2	14
135	A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.. Blood, 2009, 114, 492-492.	1.4	14
136	Novel investigational drugs active as single agents in multiple myeloma. Expert Opinion on Investigational Drugs, 2017, 26, 699-711.	4.1	13
137	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. Critical Reviews in Oncology/Hematology, 2018, 132, 9-16.	4.4	13
138	Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients. Blood, 2012, 120, 200-200.	1.4	13
139	A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethasone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients. Blood, 2013, 122, 536-536.	1.4	13
140	Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2017, 35, 8003-8003.	1.6	13
141	Bendamustine for the treatment of multiple myeloma in first-line and relapsed/refractory settings: a review of clinical trial data. Leukemia and Lymphoma, 2015, 56, 559-567.	1.3	12
142	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. Haematologica, 2021, 106, 1079-1085.	3.5	12
143	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015. Blood, 2011, 118, 475-475.	1.4	12
144	A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200) Tj ETQqO 0 0 rgBT /Overlock 10 Analysis.. Blood, 2009, 114, 350-350.	1.4	11

#	ARTICLE	IF	CITATIONS
145	Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study. <i>Blood</i> , 2011, 118, 3069-3069.	1.4	11
146	Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 2089-2089.	1.4	11
147	PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study. <i>Blood</i> , 2013, 122, 405-405.	1.4	11
148	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2014, 124, 35-35.	1.4	11
149	Pseudopyloric Metaplasia Is Not Associated With the Development of Gastric Cancer. <i>American Journal of Gastroenterology</i> , 2021, 116, 1859-1867.	0.4	10
150	Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010). <i>Blood</i> , 2014, 124, 4755-4755.	1.4	10
151	Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. <i>PLoS ONE</i> , 2015, 10, e0116966.	2.5	10
152	Multiple myeloma: is a shift toward continuous therapy needed to move forward?. Expert Review of Hematology, 2015, 8, 253-256.	2.2	9
153	Treatment of Newly Diagnosed Elderly Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 123-143.	0.5	9
154	Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. <i>Leukemia and Lymphoma</i> , 2017, 58, 552-559.	1.3	9
155	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 533-540.	0.4	9
156	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1357-1366.	2.5	8
157	Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies. <i>Blood</i> , 2012, 120, 749-749.	1.4	8
158	Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma. <i>Blood</i> , 2013, 122, 1853-1853.	1.4	8
159	A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 685-685.	1.4	8
160	Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8018-8018.	1.6	8
161	Novel treatment paradigm for elderly patients with multiple myeloma. <i>American Journal of Blood Research</i> , 2011, 1, 190-204.	0.6	8
162	Role of Consolidation/Maintenance Therapy in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S349-S354.	0.4	7

#	ARTICLE	IF	CITATIONS
163	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT) Tj ETQq1 1 0.784314 rgBT /Ove	1.3	7
164	Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. Cancers, 2019, 11, 1735.	3.7	7
165	Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN. Blood, 2011, 118, 633-633.	1.4	7
166	Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial. Blood, 2016, 128, 1141-1141.	1.4	7
167	Part II: Role of Maintenance Therapy in Transplant-Ineligible Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 43-49.	4.9	6
168	A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol. Health and Quality of Life Outcomes, 2018, 16, 127.	2.4	6
169	Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.. Blood, 2009, 114, 743-743.	1.4	6
170	Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities. Blood, 2010, 116, 781-781.	1.4	6
171	Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma. Blood, 2012, 120, 446-446.	1.4	6
172	A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients. Blood, 2016, 128, 1145-1145.	1.4	6
173	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. Journal of Clinical Oncology, 2013, 31, 8517-8517.	1.6	6
174	Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints.. Journal of Clinical Oncology, 2014, 32, 8515-8515.	1.6	6
175	Histological growth patterns and molecular analysis of resected colorectal lung metastases. Pathology Research and Practice, 2021, 222, 153414.	2.3	5
176	Have drug combinations supplanted stem cell transplantation in myeloma?. Hematology American Society of Hematology Education Program, 2012, 2012, 335-341.	2.5	5
177	Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications.. Blood, 2006, 108, 3523-3523.	1.4	5
178	The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy.. Blood, 2009, 114, 3887-3887.	1.4	5
179	A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients. Blood, 2010, 116, 1940-1940.	1.4	5
180	Analysis of Second-Line Lenalidomide Following Initial Relapse in the MM-015 Trial. Blood, 2012, 120, 944-944.	1.4	5

#	ARTICLE	IF	CITATIONS
181	Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study. <i>Blood</i> , 2014, 124, 2110-2110.	1.4	5
182	Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients. <i>Blood</i> , 2014, 124, 3423-3423.	1.4	5
183	Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study. <i>Blood</i> , 2016, 128, 3334-3334.	1.4	5
184	Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy. <i>Blood</i> , 2016, 128, 4409-4409.	1.4	5
185	Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS8609-TPS8609.	1.6	5
186	Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. <i>Cancer</i> , 2021, 127, 3413-3421.	4.1	4
187	Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach. <i>Blood</i> , 2010, 116, 3046-3046.	1.4	4
188	A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide. <i>Blood</i> , 2011, 118, 632-632.	1.4	4
189	Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2012, 120, 730-730.	1.4	4
190	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study. <i>Blood</i> , 2014, 124, 175-175.	1.4	4
191	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study. <i>Blood</i> , 2015, 126, 1828-1828.	1.4	4
192	Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial. <i>Blood</i> , 2015, 126, 392-392.	1.4	4
193	Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and -MM4.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8068-TPS8068.	1.6	4
194	Curative and Prophylactic Surgery of Young-onset Colorectal Cancer in Inherited Syndromes: A 15-Year Monocentric Retrospective Experience. <i>Anticancer Research</i> , 2019, 39, 3131-3136.	1.1	3
195	Monoclonal antibodies for treating multiple myeloma - a new era, new safety considerations?. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1295-1300.	2.4	3
196	Bortezomib Plus Melphalanâ€Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalanâ€Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.. <i>Blood</i> , 2009, 114, 3859-3859.	1.4	3
197	Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.. <i>Blood</i> , 2009, 114, 960-960.	1.4	3
198	A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2010, 116, 3573-3573.	1.4	3

#	ARTICLE	IF	CITATIONS
199	Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years Benefiting From Delays in Disease Progression. Blood, 2011, 118, 3157-3157.	1.4	3
200	Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients. Blood, 2011, 118, 996-996.	1.4	3
201	Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients. Blood, 2014, 124, 2043-2043.	1.4	3
202	The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease. Blood, 2014, 124, 3371-3371.	1.4	3
203	Sustained disease control in transplant-ineligible patients: the role of continuous therapy. Leukemia Research, 2012, 36, S19-S26.	0.8	2
204	Immunotherapy: the next step in the treatment of myeloma. Lancet Haematology, the, 2015, 2, e504-e505.	4.6	2
205	Case report: skin injury after contact with a red spine starfish, <i>Protoreaster lincki</i> . Contact Dermatitis, 2018, 78, 95-96.	1.4	2
206	Carfilzomib Combined With Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. HemaSphere, 2020, 4, e370.	2.7	2
207	Have drug combinations supplanted stem cell transplantation in myeloma?. Hematology American Society of Hematology Education Program, 2012, 2012, 335-41.	2.5	2
208	Neuropathy in Multiple Myeloma Patients Treated with Bortezomib: A Multicenter Experience.. Blood, 2007, 110, 4823-4823.	1.4	2
209	Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.. Blood, 2009, 114, 1868-1868.	1.4	2
210	Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma. Blood, 2010, 116, 525-525.	1.4	2
211	Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years,. Blood, 2011, 118, 3988-3988.	1.4	2
212	Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM. Blood, 2013, 122, 4290-4290.	1.4	2
213	In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide. Blood, 2014, 124, 3394-3394.	1.4	2
214	Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma. Blood, 2014, 124, 80-80.	1.4	2
215	Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial).. Journal of Clinical Oncology, 2018, 36, 8009-8009.	1.6	2
216	Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients. Blood, 2013, 122, 3126-3126.	1.4	2



#	ARTICLE	IF	CITATIONS
217	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood, 1993, 81, 2708-2713.	1.4	2
218	Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. Blood, 2015, 126, 927-927.	1.4	2
219	The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells. Blood, 2019, 134, 3136-3136.	1.4	2
220	Stem Cell Transplantation in Multiple Myeloma. Current Cancer Drug Targets, 2017, 17, 769-781.	1.6	2
221	Optimizing multiple myeloma treatment: conclusions. Leukemia Research, 2012, 36, S44-S45.	0.8	1
222	Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective?. Biology of Blood and Marrow Transplantation, 2015, 21, 1705-1706.	2.0	1
223	Frail Patients with Newly Diagnosed Multiple Myeloma. , 2018, , 539-549.		1
224	Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients.. Blood, 2009, 114, 3419-3419.	1.4	1
225	Analysis of Transcriptome, Mirnome and Genomic Profiles in Association with Clinical Outcome in a Prospective Series of Primary Plasma Cell Leukemia. Blood, 2012, 120, 3938-3938.	1.4	1
226	Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia. Blood, 2012, 120, 729-729.	1.4	1
227	Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM). Blood, 2012, 120, 788-788.	1.4	1
228	Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study. Blood, 2013, 122, 3212-3212.	1.4	1
229	Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network. Blood, 2014, 124, 2118-2118.	1.4	1
230	Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma. Blood, 2014, 124, 44-44.	1.4	1
231	Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival. Blood, 2015, 126, 3029-3029.	1.4	1
232	Bortezomib and Plasma Cell Leukemia.. Blood, 2006, 108, 3546-3546.	1.4	1
233	Bortezomib as Front-Line Therapy in Primary Plasma Cell Leukemia. Blood, 2008, 112, 2784-2784.	1.4	1
234	Central Nervous System and Intracranial Myeloma: a Retrospective Italian Multicenter Study.. Blood, 2009, 114, 1882-1882.	1.4	1

#	ARTICLE	IF	CITATIONS
235	Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma. Blood, 2014, 124, 4770-4770.	1.4	1
236	Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix. Blood, 2014, 124, 2051-2051.	1.4	1
237	Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice. Blood, 2015, 126, 3034-3034.	1.4	1
238	Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study. Blood, 2015, 126, 1760-1760.	1.4	1
239	Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity. Blood, 2016, 128, 2072-2072.	1.4	1
240	A new combination for advanced multiple myeloma. Lancet Oncology, The, 2011, 12, 207-208.	10.7	0
241	Latest advances in the management of elderly patients with multiple myeloma. International Journal of Hematologic Oncology, 2013, 2, 431-434.	1.6	0
242	IH2 INHIBITION ENHANCES PROTEASOME INHIBITOR RESPONSIVENESS IN HEMATOLOGICAL MALIGNANCIES. Hematological Oncology, 2019, 37, 515-515.	1.7	0
243	Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR.. Blood, 2006, 108, 3100-3100.	1.4	0
244	Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2.. Blood, 2006, 108, 3413-3413.	1.4	0
245	Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.. Blood, 2009, 114, 2877-2877.	1.4	0
246	High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease. Blood, 2010, 116, 1898-1898.	1.4	0
247	IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. Blood, 2010, 116, 2951-2951.	1.4	0
248	Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups,. Blood, 2011, 118, 3970-3970.	1.4	0
249	Evaluation of Atypical Low Energy Fractures in Patients Affected by Multiple Myeloma Treated with Bisphosphonates. Blood, 2011, 118, 5134-5134.	1.4	0
250	Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,. Blood, 2011, 118, 3989-3989.	1.4	0
251	Prioritizing Content in Continuing Hematologic Oncology Education: A Survey of 51 Clinical Investigators. Blood, 2012, 120, 4270-4270.	1.4	0
252	miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.. Blood, 2012, 120, 2921-2921.	1.4	0



#	ARTICLE	IF	CITATIONS
253	A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma. Blood, 2012, 120, 1851-1851.	1.4	0
254	Novel Agents and Autologous Stem Cell Transplantation Improve Survival of Multiple Myeloma Patients with Ages 65â€“70 Years: A Multicenter Retrospective Collaborative Study Between Japanese Society of Myeloma and European Myeloma Network. Blood, 2012, 120, 5030-5030.	1.4	0
255	Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients.. Blood, 2012, 120, 2971-2971.	1.4	0
256	High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma. Blood, 2012, 120, 4204-4204.	1.4	0
257	Lenalidomide (LEN)-melphalan-prednisone induction followed by LEN maintenance (MPR-R) in newly diagnosed multiple myeloma (NDMM) elderly patients (Pts) with moderate renal impairment (RI): MM-015 trial post-hoc analysis.. Journal of Clinical Oncology, 2013, 31, 8544-8544.	1.6	0
258	The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. Blood, 2014, 124, 4740-4740.	1.4	0
259	Virtual Karyotype Reconstruction By SNPs Array of Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the EMN02 Clinical Trial. Blood, 2014, 124, 2033-2033.	1.4	0
260	Multicolor Flowcytometry Analysis of Hematopoietic Stem and Progenitor Cells Subsets Among Basal and Mobilized Peripheral CD34+ Cells. Blood, 2014, 124, 5117-5117.	1.4	0
261	Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers. Blood, 2015, 126, 1814-1814.	1.4	0
262	Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. Blood, 2015, 126, 1974-1974.	1.4	0
263	Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.. Journal of Clinical Oncology, 2016, 34, 8031-8031.	1.6	0
264	Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs. Blood, 2016, 128, 3469-3469.	1.4	0
265	An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials. Blood, 2016, 128, 3336-3336.	1.4	0
266	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. Blood, 2016, 128, 995-995.	1.4	0
267	Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features. Blood, 2016, 128, 5625-5625.	1.4	0
268	Prognostic Implication of Somatic Mutations By Next Generation Sequencing: An Analysis from the Mmrif Commpass Study in Newly Diagnosed Multiple Myeloma Patients. Blood, 2016, 128, 2079-2079.	1.4	0
269	Risk Stratification in Newly Diagnosed Transplant Ineligible Multiple Myeloma. , 2018, , 37-58.		0